S
Signature Therapeutics, Inc.
Signature Therapeutics is focused on creating novel medicines to improve upon the therapeutic utility of existing drugs
About Signature Therapeutics, Inc.
In 2004, a clinical-stage biopharmaceutical company called Signature Therapeutics was founded by Steven Shafer. The company, initially known as PharmacoFore, set out with a specific mission: to develop abuse-resistant prescription drugs. They focused on creating prodrugs, which are inactive medications that, once taken orally, become therapeutically active through the digestive process. This innovative approach aimed to tackle the growing problem of prescription drug misuse, particularly with opioids. The core of their work was the Bio-Activated Molecular Delivery (BIO-MD™) platform. This technology was designed to prevent abuse through non-oral methods like injection or inhalation. One of their key products was PF614, an abuse-deterrent version of Oxycodone. The company attracted investment, raising $10 million in a significant funding round in December 2011 from investors including Founders Fund and Westlake International Group. The company's journey culminated in a significant event. On December 31, 2015, Signature Therapeutics merged with Ensysce Biosciences. This merger created a more integrated drug delivery company, combining Signature's focus on abuse-deterrent small molecules with Ensysce's work on large molecule delivery. The combined entity continued under the Ensysce Biosciences name, relocating from Palo Alto to San Diego to advance the clinical trials for their pipeline of safer pain medications.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2016 | $0 | — | Ensysce Biosciences | — |
| SERIES A✓Equity / VC | Dec 2011 | $10M | $40M | Founders Fund | — |
Growth signals
Latest recorded traffic for Signature Therapeutics, Inc. is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Signature Therapeutics, Inc. in the San Carlos ecosystem
The Signature Therapeutics, Inc. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors1 additional known investor
Ensysce Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Signature Therapeutics, Inc. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Signature Therapeutics, Inc.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










